Positive Airway Pressure Devices Market Size, Share & Trends Analysis Report By Product (CPAP, APAP, BiPAP), By Application (OSA, COPD), By End Use (Home Care Settings, Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2033
Description
Positive Airway Pressure Devices Market Summary
The global positive airway pressure devices market size was estimated at USD 2.48 billion in 2024 and is projected to reach USD 4.04 billion by 2033, growing at a CAGR of 5.60% from 2025 to 2033. This growth is attributed to the increasing prevalence of sleep apnea, advancements in technology, rising awareness and diagnosis of sleep disorders, and improving healthcare infrastructure.
These factors are fueling the demand for PAP devices globally. Growing health concerns, better diagnostic methods, and technological innovations are shaping the market's future growth prospects. Obstructive sleep apnea is a respiratory disorder wherein the patient faces irregular breathing patterns with reduced oxygen supply to the brain. According to the Saudi Journal of Otorhinolaryngology-Head and Neck Surgery estimates on the global prevalence of obstructive sleep apnea published in 2023, approximately 936 million people are suffering from mild to severe sleep apnea, and among these, 425 million individuals in the age group of 30 to 69 years are suffering from moderate-to-severe sleep apnea. Rapid globalization, changing lifestyles, and unhealthy dietary habits are a few factors contributing to the prevalence of sleep apnea. In addition, growing obesity levels and a lack of physical activity are driving the incidence rate of obstructive sleep apnea.
Rising awareness and diagnosis of sleep disorders are crucial factors propelling market growth. As people become more educated about sleep apnea and its potential risks, they are more likely to seek diagnosis and treatment. Public health campaigns run by organizations such as the American Sleep Apnea Association have helped improve awareness. In addition, improved diagnostic methods such as polysomnography and home sleep tests have made identifying sleep apnea in its early stages easier. The increasing recognition of sleep apnea as a significant health concern drives more individuals to pursue PAP therapy, thus fueling market demand.
The COVID-19 pandemic had a positive impact on the PAP devices market. According to a study published by the National Centre for Biotechnology Information in 2022, obstructive sleep apnea treated with home CPAP was not associated with worse outcomes in hospitalized COVID-19 patients, suggesting that CPAP can be safely continued during the pandemic. Telehealth services improved CPAP adherence, with some reports showing increased usage during lockdowns as patients received better remote support. The pandemic has highlighted the importance of PAP devices in managing sleep disorders and supporting respiratory health in critically ill patients.
Furthermore, according to ResMed's annual report for the fiscal year ending June 30, 2024, the COVID-19 pandemic impacted the company's sales, particularly in its sleep and respiratory care segment. The report indicates an increased demand for ResMed's PAP devices due to the heightened awareness of respiratory health during the pandemic. This surge in demand was driven by the need for practical, non-invasive ventilation options for patients with respiratory issues related to COVID-19. Market players such as ResMed experienced strong revenue growth in its PAP device sales, reflecting its critical role in managing sleep apnea and respiratory complications associated with COVID-19.
Global Positive Airway Pressure Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global positive airway pressure devices market report based on product, application, end use, and region:
The global positive airway pressure devices market size was estimated at USD 2.48 billion in 2024 and is projected to reach USD 4.04 billion by 2033, growing at a CAGR of 5.60% from 2025 to 2033. This growth is attributed to the increasing prevalence of sleep apnea, advancements in technology, rising awareness and diagnosis of sleep disorders, and improving healthcare infrastructure.
These factors are fueling the demand for PAP devices globally. Growing health concerns, better diagnostic methods, and technological innovations are shaping the market's future growth prospects. Obstructive sleep apnea is a respiratory disorder wherein the patient faces irregular breathing patterns with reduced oxygen supply to the brain. According to the Saudi Journal of Otorhinolaryngology-Head and Neck Surgery estimates on the global prevalence of obstructive sleep apnea published in 2023, approximately 936 million people are suffering from mild to severe sleep apnea, and among these, 425 million individuals in the age group of 30 to 69 years are suffering from moderate-to-severe sleep apnea. Rapid globalization, changing lifestyles, and unhealthy dietary habits are a few factors contributing to the prevalence of sleep apnea. In addition, growing obesity levels and a lack of physical activity are driving the incidence rate of obstructive sleep apnea.
Rising awareness and diagnosis of sleep disorders are crucial factors propelling market growth. As people become more educated about sleep apnea and its potential risks, they are more likely to seek diagnosis and treatment. Public health campaigns run by organizations such as the American Sleep Apnea Association have helped improve awareness. In addition, improved diagnostic methods such as polysomnography and home sleep tests have made identifying sleep apnea in its early stages easier. The increasing recognition of sleep apnea as a significant health concern drives more individuals to pursue PAP therapy, thus fueling market demand.
The COVID-19 pandemic had a positive impact on the PAP devices market. According to a study published by the National Centre for Biotechnology Information in 2022, obstructive sleep apnea treated with home CPAP was not associated with worse outcomes in hospitalized COVID-19 patients, suggesting that CPAP can be safely continued during the pandemic. Telehealth services improved CPAP adherence, with some reports showing increased usage during lockdowns as patients received better remote support. The pandemic has highlighted the importance of PAP devices in managing sleep disorders and supporting respiratory health in critically ill patients.
Furthermore, according to ResMed's annual report for the fiscal year ending June 30, 2024, the COVID-19 pandemic impacted the company's sales, particularly in its sleep and respiratory care segment. The report indicates an increased demand for ResMed's PAP devices due to the heightened awareness of respiratory health during the pandemic. This surge in demand was driven by the need for practical, non-invasive ventilation options for patients with respiratory issues related to COVID-19. Market players such as ResMed experienced strong revenue growth in its PAP device sales, reflecting its critical role in managing sleep apnea and respiratory complications associated with COVID-19.
Global Positive Airway Pressure Devices Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global positive airway pressure devices market report based on product, application, end use, and region:
- Product Outlook (Volume, 000`Units; Revenue, USD Million, 2021 - 2033)
- CPAP
- APAP
- BiPAP
- Application Outlook (Volume, 000`Units; Revenue, USD Million, 2021 - 2033)
- Obstructive Sleep Apnea
- Respiratory Failures
- COPD
- End Use Outlook (Volume, 000`Units; Revenue, USD Million, 2021 - 2033)
- Home Care Settings
- Hospitals & Clinics
- Others (Long-Term Care Facilities, etc.)
- Regional Outlook (Volume, 000`Units; Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR’s Internal Database
- 1.5. Details of primary research
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.1.1. Approach 1: Commodity flow approach
- 1.7.2. Volume price analysis (Model 2)
- 1.7.2.1. Approach 2: Volume price analysis
- 1.8. Research Scope and Assumptions
- 1.8.1. List of Secondary Sources
- 1.8.2. List of Primary Sources
- 1.8.3. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product Outlook
- 2.2.2. Application Outlook
- 2.2.3. End Use Outlook
- 2.2.4. Regional Outlook
- 2.3. Competitive Insights
- Chapter 3. Positive Airway Pressure Devices Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising Incidence of Obstructive Sleep Apnea (OSA)
- 3.2.1.2. Technological advancements
- 3.2.1.3. Supportive Initiatives by Government and Private Organizations for PAP Devices
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Product Recalls and Device Failures
- 3.2.2.2. Patient discomfort and compliance issues
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenges Analysis
- 3.3. Positive Airway Pressure Devices Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s Five Forces
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and Social landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Environmental landscape
- 3.3.2.5. Legal Landscape
- 3.4. Regulatory Overview
- 3.5. Technology overview (current products vs. next-gen features)
- 3.6. Major Deals & Strategic Alliances Analysis in the Positive Airway Pressure Devices
- 3.7. COVID-19 Impact
- Chapter 4. Positive Airway Pressure Devices Market: Product Estimates & Trend Analysis
- 4.1. Definition and Scope
- 4.2. Product Market Share Analysis, 2024 & 2033
- 4.3. Segment Dashboard
- 4.4. Positive Airway Pressure Devices Market: By Product, 2021 to 2033
- 4.4.1. CPAP
- 4.4.1.1. CPAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000’) Units
- 4.4.2. APAP
- 4.4.2.1. APAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000’) Units
- 4.4.3. BiPAP
- 4.4.3.1. BiPAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000’) Units
- Chapter 5. Positive Airway Pressure Devices Market: Application Estimates & Trend Analysis
- 5.1. Definition and Scope
- 5.2. Application Market Share Analysis, 2024 & 2033
- 5.3. Segment Dashboard
- 5.4. Positive Airway Pressure Devices Market: By Application, 2021 to 2033
- 5.4.1. Obstructive Sleep Apnea
- 5.4.1.1. Obstructive Sleep Apnea Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000’) Units
- 5.4.2. Respiratory Failures
- 5.4.2.1. Respiratory Failures Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000’) Units
- 5.4.3. COPD
- 5.4.3.1. COPD Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000’) Units
- Chapter 6. Positive Airway Pressure Devices Market: End Use Estimates & Trend Analysis
- 6.1. Definition and Scope
- 6.2. End Use Market Share Analysis, 2024 & 2033
- 6.3. Segment Dashboard
- 6.4. Positive Airway Pressure Devices Market: By End Use, 2021 to 2033
- 6.4.1. Hospitals and Clinics
- 6.4.1.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000’) Units
- 6.4.2. Home Care Settings
- 6.4.2.1. Home Care Settings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000’) Units
- 6.4.3. Others (Long-Term Care Facilities, etc.)
- 6.4.3.1. Others (Long-Term Care Facilities, etc.) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000’) Units
- Chapter 7. Positive Airway Pressure Devices Market: Regional Estimates & Trend Analysis by Region, Product, Application, End Use
- 7.1. Regional Dashboard
- 7.2. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.3. North America
- 7.3.1. U.S.
- 7.3.1.1. Key country dynamics
- 7.3.1.2. Regulatory framework
- 7.3.1.3. Reimbursement Scenario
- 7.3.1.4. Competitive scenario
- 7.3.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.3.2. Canada
- 7.3.2.1. Key country dynamics
- 7.3.2.2. Regulatory framework
- 7.3.2.3. Reimbursement Scenario
- 7.3.2.4. Competitive scenario
- 7.3.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.3.3. Mexico
- 7.3.3.1. Key country dynamics
- 7.3.3.2. Regulatory framework
- 7.3.3.3. Reimbursement Scenario
- 7.3.3.4. Competitive scenario
- 7.3.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework
- 7.4.1.3. Reimbursement Scenario
- 7.4.1.4. Competitive scenario
- 7.4.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.4.2. Germany
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework
- 7.4.2.3. Reimbursement Scenario
- 7.4.2.4. Competitive scenario
- 7.4.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.4.3. France
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework
- 7.4.3.3. Reimbursement Scenario
- 7.4.3.4. Competitive scenario
- 7.4.3.5. France market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.4.4. Italy
- 7.4.4.1. Key country dynamics
- 7.4.4.2. Regulatory framework
- 7.4.4.3. Reimbursement Scenario
- 7.4.4.4. Competitive scenario
- 7.4.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.4.5. Spain
- 7.4.5.1. Key country dynamics
- 7.4.5.2. Regulatory framework
- 7.4.5.3. Reimbursement Scenario
- 7.4.5.4. Competitive scenario
- 7.4.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.4.6. Denmark
- 7.4.6.1. Key country dynamics
- 7.4.6.2. Regulatory framework
- 7.4.6.3. Reimbursement Scenario
- 7.4.6.4. Competitive scenario
- 7.4.6.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.4.7. Sweden
- 7.4.7.1. Key country dynamics
- 7.4.7.2. Regulatory framework
- 7.4.7.3. Reimbursement Scenario
- 7.4.7.4. Competitive scenario
- 7.4.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.4.8. Norway
- 7.4.8.1. Key country dynamics
- 7.4.8.2. Regulatory framework
- 7.4.8.3. Reimbursement Scenario
- 7.4.8.4. Competitive scenario
- 7.4.8.5. Norway market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework
- 7.5.1.3. Reimbursement Scenario
- 7.5.1.4. Competitive scenario
- 7.5.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.5.2. China
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework
- 7.5.2.3. Reimbursement Scenario
- 7.5.2.4. Competitive scenario
- 7.5.2.5. China market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.5.3. India
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework
- 7.5.3.3. Reimbursement Scenario
- 7.5.3.4. Competitive scenario
- 7.5.3.5. India market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.5.4. South Korea
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework
- 7.5.4.3. Reimbursement Scenario
- 7.5.4.4. Competitive scenario
- 7.5.4.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.5.5. Thailand
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework
- 7.5.5.3. Reimbursement Scenario
- 7.5.5.4. Competitive scenario
- 7.5.5.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.5.6. Australia
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework
- 7.5.6.3. Reimbursement Scenario
- 7.5.6.4. Competitive scenario
- 7.5.6.5. Australia market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework
- 7.6.1.3. Reimbursement Scenario
- 7.6.1.4. Competitive scenario
- 7.6.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.6.2. Argentina
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework
- 7.6.2.3. Reimbursement Scenario
- 7.6.2.4. Competitive scenario
- 7.6.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework
- 7.7.1.3. Reimbursement Scenario
- 7.7.1.4. Competitive scenario
- 7.7.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.7.2. Saudi Arabia
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework
- 7.7.2.3. Reimbursement Scenario
- 7.7.2.4. Competitive scenario
- 7.7.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.7.3. UAE
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework
- 7.7.3.3. Reimbursement Scenario
- 7.7.3.4. Competitive scenario
- 7.7.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- 7.7.4. Kuwait
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework
- 7.7.4.3. Reimbursement Scenario
- 7.7.4.4. Competitive scenario
- 7.7.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million) (000’) Units
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis, 2024
- 8.3. Company Market Share Analysis, CPAP Devices, 2024
- 8.4. Company Market Share Analysis, APAP Devices, 2024
- 8.5. Company Market Share Analysis, Bi-PAP Devices, 2024
- 8.6. Company Categorization
- 8.7. Company Profiles/Listing
- 8.7.1. Koninklijke Philips N.V.
- 8.7.1.1. Participant’s Overview
- 8.7.1.2. Financial Performance
- 8.7.1.3. Product Benchmarking
- 8.7.1.4. Strategy Mapping
- 8.7.2. Fisher & Paykel Healthcare Limited
- 8.7.2.1. Participant’s Overview
- 8.7.2.2. Financial Performance
- 8.7.2.3. Product Benchmarking
- 8.7.2.4. Strategy Mapping
- 8.7.3. ResMed
- 8.7.3.1. Participant’s Overview
- 8.7.3.2. Financial Performance
- 8.7.3.3. Product Benchmarking
- 8.7.3.4. Strategy Mapping
- 8.7.4. Drive DeVilbiss Healthcare
- 8.7.4.1. Participant’s Overview
- 8.7.4.2. Financial Performance
- 8.7.4.3. Product Benchmarking
- 8.7.4.4. Strategy Mapping
- 8.7.5. React Health (3B Medical)
- 8.7.5.1. Participant’s Overview
- 8.7.5.2. Financial Performance
- 8.7.5.3. Product Benchmarking
- 8.7.5.4. Strategy Mapping
- 8.7.6. BMC Medical
- 8.7.6.1. Participant’s Overview
- 8.7.6.2. Financial Performance
- 8.7.6.3. Product Benchmarking
- 8.7.6.4. Strategy Mapping
- 8.7.7. Armstrong Medical Inc.
- 8.7.7.1. Participant’s Overview
- 8.7.7.2. Financial Performance
- 8.7.7.3. Product Benchmarking
- 8.7.7.4. Strategy Mapping
- 8.7.8. Wellell (Apex Medical)
- 8.7.8.1. Participant’s Overview
- 8.7.8.2. Financial Performance
- 8.7.8.3. Product Benchmarking
- 8.7.8.4. Strategy Mapping
- 8.7.9. Breas Medical
- 8.7.9.1. Participant’s Overview
- 8.7.9.2. Financial Performance
- 8.7.9.3. Product Benchmarking
- 8.7.9.4. Strategy Mapping
- 8.7.10. SEFAM
- 8.7.10.1. Participant’s Overview
- 8.7.10.2. Financial Performance
- 8.7.10.3. Product Benchmarking
- 8.7.10.4. Strategy Mapping
- 8.7.11. Trudell Medical (Vyaire)
- 8.7.11.1. Participant’s Overview
- 8.7.11.2. Financial Performance
- 8.7.11.3. Product Benchmarking
- 8.7.11.4. Strategy Mapping
- 8.7.12. Löwenstein Medical UK Ltd
- 8.7.12.1. Participant’s Overview
- 8.7.12.2. Financial Performance
- 8.7.12.3. Product Benchmarking
- 8.7.12.4. Strategy Mapping
- 8.7.13. Transcend Inc. (Somnetics International, Inc.)
- 8.7.13.1. Participant’s Overview
- 8.7.13.2. Financial Performance
- 8.7.13.3. Product Benchmarking
- 8.7.13.4. Strategy Mapping
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
